AFFILIATIONS
1 Emergency Department, Henri-Mondor University Hospital, Greater Paris University Hospitals, Créteil, France, Erythrocyte Sickle Cell Disease Network, Créteil, France
2 Erythrocyte Sickle Cell Disease Network, Créteil, France, Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, Université Paris Est- Créteil (UPEC), Créteil, France, Internal Medicine Department, Henri Mondor Hospital, Créteil, France
3 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Research and Control Centre, University of Bamako, Bamako, Mali
4 Clinical Research Unit, Brugmann Hospital, Brussels, Belgium
5 Erythrocyte Sickle Cell Disease Network, Créteil, France, Faculty of Health Sciences, University of Lomé, Lomé, Togo, National Center for Research and Care for Sickle Cell Patients, Lomé, Togo
6 Department of Hematology, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
7 Division of Hematology-Oncology, Centre hospitalier universitaire (CHU) Sainte-Justine, Montréal, Canada, Erythrocyte Sickle Cell Disease Network, Créteil, France
8 McGill University, Montreal, Canada
9 INNOVHEM, Évry-Courcouronnes, France
10 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
11 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
12 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
13 Erythrocyte Sickle Cell Disease Network, Créteil, France, Internal Medicine Department, Henri Mondor Hospital, Créteil, France
14 Erythrocyte Sickle Cell Disease Network, Créteil, France, Internal Medicine Department, French National Sickle Cell Disease Referral Center, European Hospital Georges Pompidou, Greater Paris University Hospitals, Paris Cité University, Paris, France
15 Department of Internal Medicine, Louis-Mourier Hospital Colombes, Greater Paris University Hospitals, Paris Cité University, Paris, France, Erythrocyte Sickle Cell Disease Network, Créteil, France
16 Erythrocyte Sickle Cell Disease Network, Créteil, France, Internal Medicine Department, French National Sickle Cell Disease Competence Center, Delafontaine Hospital, Saint-Denis, France
17 Emergency Department, Hospital Tenon, Paris, France, Erythrocyte Sickle Cell Disease Network, Créteil, France
18 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
19 Emergency Department, Henri-Mondor University Hospital, Greater Paris University Hospitals, Créteil, France, Erythrocyte Sickle Cell Disease Network, Créteil, France
20 Erythrocyte Sickle Cell Disease Network, Créteil, France, Laboratory of Excellence, Mondor Institute for Biomedical Research, Paris-East Créteil University, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
21 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Research and Control Centre, University of Bamako, Bamako, Mali
22 Erythrocyte Sickle Cell Disease Network, Créteil, France, Sickle Cell Research and Control Centre, University of Bamako, Bamako, Mali
23 Erythrocyte Sickle Cell Disease Network, Créteil, France, Laboratory of Excellence, Mondor Institute for Biomedical Research, Paris-East Créteil University, Créteil, France, Sickle Cell Referral Center, Henri-Mondor University Hospital, Greater Paris University Hospitals, Paris-East Créteil University, Créteil, France
ABSTRACT
Background: In sickle cell disease (SCD), not all acute pain presentations correspond to true vaso-occlusive crisis (VOC). Chronic pain, including pain amplified by prolonged opioid exposure, may mimic VOC and complicate emergency department management. This issue is especially relevant in clinical trials, where inclusion of painful episodes not truly related to VOC may dilute treatment effects, bias endpoint assessment, and weaken the interpretation of efficacy results. A simple admission-based tool to support VOC diagnosis would therefore be useful both in routine care and in studies of acute painful events.
Objective: To derive and externally validate a simple biological score, based on admission laboratory values only, to support the diagnosis of VOC in SCD.
Methods: PRESEV1 was a prospective study in which patients presenting to the emergency department with suspected VOC were evaluated by expert physicians and underwent laboratory testing both at presentation and at steady state, defined at least 1 month from any VOC and at least 3 months from transfusion. In the derivation phase, acute and steady-state samples from the same patient were compared using paired univariable analyses to identify variables associated with acute VOC. Candidate admission biomarkers were then entered into multivariable logistic regression models discriminating acute from steady-state visits. To obtain a bedside tool, continuous variables were converted into rounded thresholds and simple rules were compared according to discrimination and diagnostic performance, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). External validation was performed on two independent international cohorts: PRESEV2, which included patients with VOC, and FCDREP, which included patients at steady state.
Results: In PRESEV1, 223 patients had paired acute and steady-state samples available for analysis. Paired analyses identified leukocytosis, inflammation, and hemolysis-related markers as the main correlates of acute VOC. The final rule assigned 1 point each for leukocytes >=10 G/L, C-reactive protein (CRP) >=20 mg/L, and lactate dehydrogenase (LDH) >=350 IU/L, and classified VOC as likely when at least 2 of 3 criteria were present. In PRESEV1, this rule yielded an area under the curve of 0.783, with 69.5% sensitivity, 81.2% specificity, 77.7% PPV, and 73.9% NPV. In PRESEV2, 337 patients had all 3 variables available, and 259/337 (76.9%) fulfilled the rule, including 149/337 (44.2%) with a score of 2/3 and 110/337 (32.6%) with a score of 3/3. In the FCDREP cohort, 264 patients at steady state had all three variables available; 49/264 (18.6%) were misclassified as having a VOC.
Conclusion: A simple score based on leukocyte count, CRP, and LDH may support the diagnosis of VOC. Beyond emergency care, such a tool may help standardize the definition of acute painful events and reduce misclassification in clinical trials evaluating VOC.